National Institute of Allergy & Infectious Diseases: Experimental COVID-19 Vaccine Safe, Generates Immune Response
July 15, 2020
July 15, 2020
WASHINGTON, July 15 -- The U.S. Department of Health and Human Services' National Institute of Allergy and Infectious Diseases issued the following news release:
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online in the New England Journal of Medicine. The . . .
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online in the New England Journal of Medicine. The . . .